Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

L Klimek1, U Förster-Ruhrmann2, H Olze2

  • 1Zentrum für Rhinologie und Allergologie, Wiesbaden.

Laryngo- Rhino- Otologie
|September 23, 2022
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the interpretation of neck CT/MRI scans by ChatGPT-4V for detecting primary oropharyngeal squamous cell carcinoma: An exploratory study.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

[Use of Omalizumab-biosimilars for CRSwNP in the German Health Care System - a Position Paper of the German Societies for Allergy AeDA and ORL DGHNO-KHC].

Laryngo- rhino- otologie·2026
Same author

Lack of De-Intensification Models for Female Head and Neck Cancer Patients With Favorable Prognosis.

Cancer medicine·2026
Same author

[Different immunological types of CRSwNP in the context of the new European EAACI nomenclature : Part 3: Hypersensitivity reactions of type VI].

HNO·2026
Same author

[Different immunological types of CRSwNP in the context of the new European EAACI nomenclature : Part 2: Hypersensitivity reactions of type V (epithelial barrier defects)].

HNO·2025
Same author

Olfactory implants: international opinion paper on emerging technologies and clinical applications.

Rhinology·2025
Same journal

Laryngo- rhino- otologie·2026
Same journal

Laryngo- rhino- otologie·2026
Same journal

Laryngo- rhino- otologie·2026
Same journal

[Otitis media - update on clinical presentation, diagnosis and therapy].

Laryngo- rhino- otologie·2026
Same journal

[Diagnostic error "acute otitis media"].

Laryngo- rhino- otologie·2026
Same journal

[Pharyngeal high‑resolution manometry: techniques and applications].

Laryngo- rhino- otologie·2026
See all related articles
Summary
This summary is machine-generated.

This study provides expert recommendations for monitoring and discontinuing dupilumab therapy in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) in Germany. It addresses the need for clear guidelines on managing this Type-2 inflammatory condition.

Area of Science:

  • Immunology of respiratory diseases
  • Pharmacology of biologic therapies
  • Clinical management of CRSwNP

Context:

  • Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex inflammatory condition often driven by Type-2 inflammation.
  • Dupilumab, an anti-IL-4/-IL-13 antibody, is approved for severe CRSwNP unresponsive to conventional treatments.
  • There is a lack of established guidelines for monitoring and discontinuing dupilumab in the German healthcare system.

Purpose:

  • To establish expert recommendations for the follow-up, therapy breaks, intervals, and discontinuation of dupilumab in CRSwNP patients within the German healthcare system.
  • To provide a framework for managing dupilumab therapy based on international literature and expert consensus.
  • To address the clinical need for structured guidance on biologic therapy for severe CRSwNP.

Related Experiment Videos

Summary:

  • An expert panel reviewed existing literature and clinical experience to develop recommendations for dupilumab therapy in CRSwNP.
  • The recommendations cover crucial aspects of treatment management, including patient monitoring, temporary therapy cessation, and criteria for treatment termination.
  • A documentation form is proposed to support the implementation of these guidelines.

Impact:

  • Facilitates consistent and evidence-based management of dupilumab therapy for severe CRSwNP in Germany.
  • Aims to optimize treatment outcomes and resource utilization for patients with this challenging condition.
  • Supports clinicians in making informed decisions regarding the long-term use of dupilumab.